A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

NCT06675175 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Atherosclerotic Cardiovascular Disease

Interventions

DRUG: AZD4144
OTHER: Placebo

Sponsor

AstraZeneca